Pancreatic cancer has no single cause. It develops when cells in the pancreas accumulate genetic damage that allows them to grow uncontrollably, and that damage results from a combination of inherited traits, lifestyle factors, and chronic disease. An estimated 67,530 new cases will be diagnosed in the United States in 2026, with roughly 52,740 deaths, making it one of the deadliest cancers largely because it’s so difficult to detect early.
The Genetic Mutations That Drive It
Nearly all pancreatic cancers are ductal adenocarcinomas, and the vast majority share a common genetic fingerprint. A mutation in the KRAS gene appears in roughly 87 to 91 percent of cases across large genomic studies. KRAS acts like a stuck accelerator pedal: normally it tells a cell when to grow and when to stop, but once mutated, it signals the cell to keep dividing without pause.
KRAS alone isn’t enough. Up to three-quarters of pancreatic cancers also carry mutations in TP53, a gene that normally acts as a brake on damaged cells by triggering their self-destruction. When TP53 stops working, cells that should die instead survive and multiply. Two other tumor-suppressor genes, CDKN2A and SMAD4, are each mutated in about 20 percent of cases. Together, these four genes form the core machinery behind most pancreatic tumors: one gene jammed in the “on” position and several safety switches knocked out.
How Normal Cells Become Cancerous
Pancreatic cancer doesn’t appear overnight. It progresses through precursor stages that can take years, sometimes more than a decade, to become invasive. The most common precursor is called a PanIN, a microscopic change in the cells lining the pancreatic ducts. These lesions progress in a stepwise fashion from low-grade abnormalities to high-grade ones and eventually to full-blown cancer. Think of it as a slow accumulation of errors: each new mutation pushes the cells one step closer to uncontrolled growth.
A second type of precursor, called an IPMN, is a visible growth inside the pancreatic duct that produces mucus. IPMNs are more complex. Researchers have identified at least three distinct pathways by which they can give rise to invasive cancer, including a sequential progression similar to PanINs, a “branch-off” route where cancer develops alongside the IPMN, and a pathway where cancer arises independently nearby. IPMNs vary in their grade and cell type, which is why some are closely monitored while others are surgically removed.
Inherited Risk and Family History
About 5 to 10 percent of pancreatic cancers have a hereditary component. Several specific genetic syndromes dramatically increase lifetime risk:
- Hereditary pancreatitis (PRSS1 gene): People born with this condition face roughly a 40 percent lifetime risk of developing pancreatic cancer, partly because their pancreas is chronically inflamed from a young age.
- Peutz-Jeghers syndrome (STK11 gene): About 35 percent of people with this syndrome develop pancreatic cancer by age 60.
- Familial melanoma syndrome (CDKN2A gene): Inherited mutations in this gene carry a 15 to 35 percent lifetime risk of pancreatic cancer, in addition to the melanoma risk.
Mutations in BRCA1 and BRCA2, best known for their role in breast and ovarian cancer, also raise pancreatic cancer risk. If you have two or more first-degree relatives who’ve had pancreatic cancer, or you carry one of these known gene mutations, you fall into a high-risk category where surveillance imaging may be recommended. For the general population, however, routine screening is not advised because no test is accurate enough to catch early-stage disease without generating a high rate of false alarms.
Smoking
Smoking is the most significant modifiable risk factor. People who smoke are about twice as likely to develop pancreatic cancer compared to people who have never smoked. The chemicals in tobacco reach the pancreas through the bloodstream after being absorbed in the lungs, and over time they contribute to the kind of DNA damage that initiates tumor growth. The good news is that risk begins to decline after quitting, though it takes years to approach the baseline risk of someone who never smoked.
Obesity, Diabetes, and Chronic Inflammation
People with a BMI of 30 or higher are about 20 percent more likely to develop pancreatic cancer than people at a healthy weight. Excess body fat promotes low-grade, persistent inflammation throughout the body, and the pancreas is particularly vulnerable to this because it sits in an environment where fat tissue, digestive enzymes, and metabolic hormones constantly interact.
The relationship between diabetes and pancreatic cancer runs in both directions. Long-standing type 2 diabetes modestly raises pancreatic cancer risk, likely through chronic inflammation and metabolic stress in the organ. But new-onset diabetes in someone over 50, especially without the typical risk factors like obesity or family history, can sometimes be an early signal that a pancreatic tumor is already growing and disrupting the organ’s ability to regulate blood sugar. The underlying biology involves inflammatory changes in the pancreas that simultaneously worsen insulin resistance and create a favorable environment for tumor cells.
Chronic pancreatitis, long-term inflammation of the pancreas from any cause, is another well-established risk factor. Years of repeated tissue damage and repair give cells more opportunities to acquire the mutations that lead to cancer. This is one reason hereditary pancreatitis carries such a high lifetime risk: the inflammation starts early and never fully resolves.
Alcohol and Its Indirect Role
Heavy alcohol use doesn’t appear to directly cause pancreatic cancer in the way smoking does, but it raises risk indirectly. Chronic heavy drinking is a leading cause of pancreatitis, and that sustained inflammation is the bridge to cancer. Moderate drinking has not been consistently linked to increased risk, so the concern is really about patterns of consumption heavy enough to damage the pancreas over time.
Occupational and Chemical Exposures
Certain workplace exposures have been associated with higher rates of pancreatic cancer, though pinning down the exact chemicals responsible has proven difficult. Workers in steel mills, aluminum production facilities, and rubber and printing industries have shown elevated risk in occupational studies. Some of the strongest links have been to specific industrial chemicals like benzidine and beta-naphthylamine, both used in dye manufacturing. Leather tanning workers, sheet metal workers, and people in textile and food processing have also shown increased rates in some studies, though researchers often couldn’t isolate the specific agent responsible. Long-duration exposure, 20 years or more in some studies, seems to matter most.
Age, Sex, and Race
Pancreatic cancer is overwhelmingly a disease of older adults. The average age at diagnosis is in the late 60s to early 70s, and cases before age 45 are rare outside of inherited syndromes. Men develop pancreatic cancer at slightly higher rates than women, a gap that likely reflects historical differences in smoking rates and occupational exposures. Black Americans face a notably higher incidence than white Americans, a disparity that researchers attribute to a combination of higher rates of diabetes, smoking, and obesity in that population, along with potential differences in access to care and genetic susceptibility that are still being studied.
The overall incidence rate in the U.S. is 13.9 per 100,000 people per year, and the death rate of 11.3 per 100,000 reflects just how lethal this cancer remains. Those two numbers being so close together tells you something important: most people diagnosed with pancreatic cancer will ultimately die from it, which is why understanding and reducing risk factors matters so much.